A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

Corina Serban; Amirhossein Sahebkar; Sorin Ursoniu; Dimitri P Mikhailidis; Manfredi Rizzo; Gregory Y H Lip; G Kees Hovingh; John J P Kastelein; Leszek Kalinowski; Jacek Rysz; Maciej Banach

doi:10.1038/srep09902

A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

Corina Serban, Amirhossein Sahebkar, Sorin Ursoniu, Dimitri P Mikhailidis, Manfredi Rizzo, Gregory Y H Lip, G Kees Hovingh, John J P Kastelein, Leszek Kalinowski, Jacek Rysz, Maciej Banach

Research output: Contribution to journal › Review article › peer-review

143 Citations (Scopus)

Abstract

The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: - 0.104 μM, 95% confidence interval: - 0.131 to - 0.077, Z = - 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: - 0.207 μM, 95%CI: - 0.427 to + 0.013, Z = - 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: - 0.101 μM, 95%CI: - 0.128 to - 0.074, Z = - 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.

Original language	English
Journal	Scientific Reports
Volume	5
Pages (from-to)	9902
ISSN	2045-2322
DOIs	https://doi.org/10.1038/srep09902
Publication status	Published - 2015
Externally published	Yes

Access to Document

10.1038/srep09902

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{6ad8a7ee187f4ce6819209b238b06bb2,

title = "A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations",

abstract = "The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: - 0.104 μM, 95% confidence interval: - 0.131 to - 0.077, Z = - 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: - 0.207 μM, 95%CI: - 0.427 to + 0.013, Z = - 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: - 0.101 μM, 95%CI: - 0.128 to - 0.074, Z = - 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.",

author = "Corina Serban and Amirhossein Sahebkar and Sorin Ursoniu and Mikhailidis, {Dimitri P} and Manfredi Rizzo and Lip, {Gregory Y H} and {Kees Hovingh}, G and Kastelein, {John J P} and Leszek Kalinowski and Jacek Rysz and Maciej Banach",

year = "2015",

doi = "10.1038/srep09902",

language = "English",

volume = "5",

pages = "9902",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

AU - Serban, Corina

AU - Sahebkar, Amirhossein

AU - Ursoniu, Sorin

AU - Mikhailidis, Dimitri P

AU - Rizzo, Manfredi

AU - Lip, Gregory Y H

AU - Kees Hovingh, G

AU - Kastelein, John J P

AU - Kalinowski, Leszek

AU - Rysz, Jacek

AU - Banach, Maciej

PY - 2015

Y1 - 2015

N2 - The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: - 0.104 μM, 95% confidence interval: - 0.131 to - 0.077, Z = - 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: - 0.207 μM, 95%CI: - 0.427 to + 0.013, Z = - 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: - 0.101 μM, 95%CI: - 0.128 to - 0.074, Z = - 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.

AB - The impact of statin therapy on plasma asymmetric dimethylarginine (ADMA) levels has not been conclusively studied. Therefore the aim of the meta-analysis was to assess the effect of statins on circulating ADMA levels. We searched selected databases (up to August 2014) to identify randomized controlled trials (RCTs) that investigate the effect of statins on plasma ADMA concentrations. A weighted meta-regression (WMD) using unrestricted maximum likelihood model was performed to assess the impact of statin dose, duration of statin therapy and baseline ADMA concentrations as potential variables on the WMD between statin and placebo group. In total, 1134 participants in 9 selected RCTs were randomized; 568 were allocated to statin treatment and 566 were controls. There was a significant reduction in plasma ADMA concentrations following statin therapy compared with placebo (WMD: - 0.104 μM, 95% confidence interval: - 0.131 to - 0.077, Z = - 7.577, p < 0.0001). Subgroups analysis has shown a significant impact of hydrophilic statins (WMD: - 0.207 μM, 95%CI: - 0.427 to + 0.013, Z = - 7.250, p < .0001) and a non-significant effect of hydrophobic statins (WMD: - 0.101 μM, 95%CI: - 0.128 to - 0.074, Z = - 1.845, p = 0.065). In conclusion, this meta-analysis of available RCTs showed a significant reduction in plasma ADMA concentrations following therapy with hydrophilic statins.

U2 - 10.1038/srep09902

DO - 10.1038/srep09902

M3 - Review article

C2 - 25970700

SN - 2045-2322

VL - 5

SP - 9902

JO - Scientific Reports

JF - Scientific Reports

ER -

A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations

Abstract

Access to Document

AUB Link

Fingerprint

Cite this